Literature DB >> 3086130

Sustained intrauterine release of levonorgestrel over five years.

C G Nilsson, P L Lahteenmaki, T Luukkainen, D N Robertson.   

Abstract

Two models of levonorgestrel-releasing intrauterine devices were studied. Model A was designed to deliver 20 micrograms/day, and model B was designed to deliver 30 micrograms/day. Plasma concentrations of levonorgestrel were determined in blood samples taken from women who used the levonorgestrel-releasing intrauterine devices (IUDs) and who participated in a clinical trial for more than 5 years. During clinical studies IUDs have been removed for various reasons between 8 and 40 months after insertion. The rate of release of levonorgestrel from the IUDs was calculated by determining the remaining amount of levonorgestrel. Plasma concentrations of levonorgestrel ranged between a mean +/- standard deviation (SD) concentration of 166 +/- 75 pg/ml and 131 +/- 32 pg/ml for the first 18 months of use and between 101 +/- 37 pg/ml and 74 +/- 15 pg/ml at 24 and 60 months after insertion of the IUD. The plasma concentrations from 24 months through 60 months were significantly lower than concentrations measured during initial months of IUD use, but not between the two devices. There was a strong correlation between the time of use and the amount of levonorgestrel lost from the IUDs. The calculated mean daily release of levonorgestrel was 17.6 micrograms for model A and 22.2 micrograms for model B. This gives a calculated lifetime of more than 6 years for a levonorgestrel-releasing IUD.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Effectiveness; Contraceptive Methods; Endocrine System; Evaluation; Examinations And Diagnoses; Family Planning; Hormones; Iud; Iud, Hormone Releasing; Laboratory Examinations And Diagnoses; Laboratory Procedures; Levonorgestrel; Measurement; Physiology; Qualitative Evaluation; Reproductive Control Agents; Research Methodology; Use-effectiveness

Mesh:

Substances:

Year:  1986        PMID: 3086130     DOI: 10.1016/s0015-0282(16)49397-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  13 in total

Review 1.  A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.

Authors:  F Sturridge; J Guillebaud
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

2.  Hormonal contraception and breast cancer.

Authors:  Carolyn L Westhoff; Malcolm C Pike
Journal:  Contraception       Date:  2018-09       Impact factor: 3.375

3.  Levonorgestrel hormone releasing intrauterine system (Mirena) as a contraceptive in egg donors: case report.

Authors:  C Kailasam; V Akande; U D Gordon
Journal:  J Assist Reprod Genet       Date:  2005-03       Impact factor: 3.412

4.  A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.

Authors:  Shweta R Ugaonkar; Asa Wesenberg; Jolanta Wilk; Samantha Seidor; Olga Mizenina; Larisa Kizima; Aixa Rodriguez; Shimin Zhang; Keith Levendosky; Jessica Kenney; Meropi Aravantinou; Nina Derby; Brooke Grasperge; Agegnehu Gettie; James Blanchard; Narender Kumar; Kevin Roberts; Melissa Robbiani; José A Fernández-Romero; Thomas M Zydowsky
Journal:  J Control Release       Date:  2015-06-17       Impact factor: 9.776

5.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Hormonal contraception and breast cancer.

Authors:  Carolyn L Westhoff; Malcolm C Pike
Journal:  Am J Obstet Gynecol       Date:  2018-05-17       Impact factor: 8.661

Review 7.  Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.

Authors:  S Mantha; R Karp; V Raghavan; N Terrin; K A Bauer; J I Zwicker
Journal:  BMJ       Date:  2012-08-07

8.  Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.

Authors:  Paula H Bednarek; Jeffrey T Jensen
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Role of the levonorgestrel intrauterine system in effective contraception.

Authors:  Abdelhamid M Attia; Magdy M Ibrahim; Ahmed M Abou-Setta
Journal:  Patient Prefer Adherence       Date:  2013-08-09       Impact factor: 2.711

Review 10.  Femilis(®) 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience.

Authors:  Dirk Wildemeersch; Amaury Andrade; Norman Goldstuck
Journal:  Clin Med Insights Reprod Health       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.